# Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features

Study · id `cardio:ct-nct05131139` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05131139](<https://clinicaltrials.gov/study/NCT05131139>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05131139

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

## Technical summary

Registry record NCT05131139. Allocation not applicable; no masking; primary purpose diagnostic. Start 2021-10-20 (actual); primary completion 2025-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT05131139, source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)
- Started: 2021-10-20 (actual) (ClinicalTrials.gov record NCT05131139, source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)
- Primary completion: 2025-03-30 (anticipated) (ClinicalTrials.gov record NCT05131139, source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)
- Completion: 2025-09-30 (anticipated) (ClinicalTrials.gov record NCT05131139, source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05131139, source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05131139-2023-04-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
- Condition: Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Continuous Glucose Monitoring System
- Lead sponsor: Senseonics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Senseonics, Inc. (`cardio:org-senseonics-inc`)

## Provenance

Content hash: 0315fec18485cd653751d3a80071c21ed91c3b7d387ed8890de6d706a83eb0a3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
